

Huntsville Hospital Health System signs five-year Salix® commercial agreement First SAPHIRE Study participant converts to commercial customer demonstrating Artrya's U.S. go-to-market strategy

Investor Conference Call at 12.00pm AEDT (9.00am AWST) on Wednesday, 7 October 2026

PERTH, Australia, 02 October 2026: Artrya Limited (ASX: AYA) (**Artrya** or the **Company**), a medical technology company commercialising its Salix® AI-powered cloud platform, for the real time, point of care assessment and management of coronary artery disease globally, is pleased to announce the signing of a five-year commercial agreement with Huntsville Hospital Health System (HH Health). The agreement marks the first conversion of a SAPHIRE Study participant into a commercial customer and represents an important milestone in Artrya's U.S. commercial strategy.

Key Points

- **First SAPHIRE commercial conversion – HH Health becomes Artrya's fourth U.S. commercial customer and the first SAPHIRE Study participant to enter into a commercial agreement for clinical use of Salix®**
- **Five-year commercial agreement with recurring and usage-based revenue model – minimum contracted value of US\$0.5M for Salix® Coronary Anatomy, with additional fee-per-scan revenue from Salix® Coronary Plaque, and Salix® Coronary Flow once FDA cleared**
- **Enterprise-scale deployment – Salix® will be integrated into applicable clinical workflows across HH Health's 15-hospital network, representing Artrya's largest U.S. customer deployment to date**
- **Validation of U.S. strategy – the first SAPHIRE-to-commercial conversion demonstrates the potential for Artrya's clinical research relationships to progress into long-term commercial adoption**

John Konstantopoulos, Co-Founder and CEO of Artrya, commented:

"The conversion of HH Health from a SAPHIRE Study participant into a commercial customer is an important milestone for Artrya's U.S. strategy.

A key objective of SAPHIRE is to establish deep clinical engagement with U.S. cardiovascular centres and create a pathway toward broader commercial adoption of Salix®. Huntsville becoming the first SAPHIRE participant to enter into a five-year commercial agreement demonstrates that strategy in action.

Importantly, this is a multi-module commercial relationship. The agreement establishes recurring SaaS revenue from Salix® Coronary Anatomy, with additional fee-per-scan revenue from Salix® Coronary Plaque and, following FDA clearance, Salix® Coronary Flow.

With HH Health joining Tanner Health, Northeast Georgia Health System and Cone Health, Artrya now has four U.S. commercial customers. Our focus is on successfully deploying Salix® across these customers while continuing to progress our SAPHIRE relationships and broader U.S. commercial activities."

First SAPHIRE partner conversion advances U.S. commercial strategy

The five-year agreement with HH Health marks Artrya's first commercial conversion from its SAPHIRE Study network and expands the Company's U.S. commercial customer base from three to four.

SAPHIRE forms part of Artrya's broader U.S. clinical and commercial strategy, establishing collaborations with leading and high-volume cardiovascular centres while providing participating organisations with direct exposure to the Salix®

platform. HH Health's progression from SAPPHIRE participant to commercial customer provides the first example of this strategy progressing from clinical research engagement to commercial adoption.

Under the agreement, Salix® Coronary Anatomy will generate recurring SaaS subscription revenue, with additional fee-per-scan revenue from CCTA assessments performed with Salix® Coronary Plaque and, following FDA clearance, Salix® Coronary Flow. The US\$0.5M minimum contracted value relates to Salix® Coronary Anatomy and does not include potential additional usage-based revenue from assessments with the Plaque and Flow modules.

Artrya will continue to progress its relationships with other SAPPHIRE participants alongside its broader U.S. commercial activities.

Enterprise-scale U.S. deployment

HH Health is Artrya's largest customer to date, and the agreement extends Artrya's relationship with HH Health beyond its SAPPHIRE research collaboration into routine clinical use across applicable clinical workflows within the broader health system.

HH Health joins Tanner Health, Northeast Georgia Health System and Cone Health as Artrya's fourth U.S. commercial customer and represents Artrya's largest U.S. customer deployment to date.

Material terms of the agreement

The full details of the Commercial Agreement are commercial in confidence, with the material points as follows:

- Commercial SaaS Licence Agreement for non-exclusive use of the Salix® Coronary Anatomy platform for clinical use
- Monthly subscription fee over the duration for use of the Salix® Coronary Anatomy platform
- Fee-per-scan revenue for Salix® Coronary Plaque, eligible for U.S. reimbursement under a Category I CPT code
- Fee-per-scan revenue for Salix® Coronary Flow, eligible for U.S. reimbursement under a Category I CPT code once FDA cleared
- 5-year term for the agreement with standard provisions for events of default
- 5-year term subject to customary termination provisions
- Customary terms include security and privacy protocols, support levels, software upgrades.

Investor Webinar

The Company's Co-Founder and CEO John Konstantopoulos, will host an Investor Webinar at **12.00pm AEDT (9.00am AWST)** on **Wednesday, 7 October 2026**, to discuss the HH Health announcement. A recording of the webinar will be available on the Investor Centre section of the Company's website for 60 days after the call. Shareholders will also have an opportunity to participate in a Q&A session at the end of the briefing.

Date: **7 October 2026**

Time: **12.00pm AEDT / 9.00am AWST**

To pre-register for this conference, please use the following link below:

[Webinar Registration - Zoom](#)

- Ends -

This ASX Announcement is authorised for release by the Board of Artrya Limited.

About Artrya

Artrya Limited (ASX:AYA) is an Australian medical technology company developing AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary software analyses coronary CT scans to identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently. Artrya's mission is to advance cardiac care through innovative technology, with regulatory and commercial activities underway across key international markets.

For more information visit www.artrya.com or follow us on LinkedIn at www.linkedin.com/company/artrya

For more information:

Corporate Enquiries

John Konstantopoulos

Co-Founder and Chief Executive Officer

Tel: +61 8 6478 7816

Email: contact@artrya.com

Investor & Media Enquiries

David Allen or John Granger

Hawkesbury Partners

Tel: +61 499 100 038 or +61 410 577 155

Email: investors@artrya.com

Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (**Estimates and Projections**). Forward-looking statements can generally be identified by the use of forward-looking words such as “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target”, “outlook”, “guidance” and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of Artrya. The Estimates and Projections are based on information available to Artrya as at the date of the Announcement, are based upon management's current expectations, estimates, projections, assumptions and beliefs in regards to future events in respect to Artrya's business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of Artrya and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by Artrya in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. Artrya takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.